Emerging Technologies for Diabetes Care

被引：31

作者：

Bailey, Timothy S. ^{[1
]}

Walsh, John ^{[2
]}

Stone, Jenine Y. ^{[1
]}

机构：

[1] AMCR Inst, 625 West Citracado Pkwy,Suite 112, Escondido, CA 92025 USA

[2] Adv Metab Care Res, Escondido, CA USA

来源：

DIABETES TECHNOLOGY & THERAPEUTICS | 2018年 / 20卷

关键词：

Diabetes technology; Glucose sensors; Connected care; Computer decision support; Insulin pumps; Insulin therapy; ACTING INSULIN ASPART; G5 CGM SYSTEM; GLYCEMIC CONTROL; PRACTICAL APPROACH; TREND ARROWS; BARRIERS; EFFICACY; TRIALS; ADULTS;

D O I：

10.1089/dia.2018.0115

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

New therapies, monitoring, and revolutionary enabling technologies applied to healthcare represent an historic opportunity to improve the lives of people with diabetes. These advances enable more meaningful monitoring of blood glucose values with the facilitation of more optimal insulin dosing and delivery. Newer insulins and delivery systems are in development that seek to mitigate both hyperglycemia and hypoglycemia and increase time in range. Information systems now exist that may be leveraged to merge data from previously discrete systems into new models of connected care. This review highlights important developments that serve to increase effectiveness while reducing the burden of diabetes care in the near future.

引用

页码：78 / 84

页数：7

共 60 条

[1]

Afrezza, 2014, AFR PRESCR INF

[2]

Agrawal P, 2017, DIABETES, V66, pA17

[3]

Aleppo G, 2017, J ENDOCR SOC, V1, P1445, DOI 10.1210/js.2017-00388

[4]

Angelo Robert, 2009, J Diabetes Sci Technol, V3, P545

[5]

[Anonymous], 2016, GLOB REP DIAB GEN

[6] AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2016 OUTPATIENT GLUCOSE MONITORING CONSENSUS STATEMENT [J].

Bailey, Timothy S. ;

Grunberger, George ;

Bode, Bruce W. ;

Handelsman, Yehuda ;

Hirsch, Irl B. ;

Jovanovic, Lois ;

Roberts, Victor Lawrence ;

Rodbard, David ;

Tamborlane, William V. ;

Walsh, John .

ENDOCRINE PRACTICE, 2016, 22 (02) :231-261

[7] Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart [J].

Basu, Ananda ;

Pieber, Thomas R. ;

Hansen, Ann K. ;

Sach-Friedl, Stefanie ;

Erichsen, Lars ;

Basu, Rita ;

Haahr, Hanne .

DIABETES OBESITY & METABOLISM, 2018, 20 (07) :1615-1622

[8] The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading [J].

Beck, Roy W. ;

Connor, Crystal G. ;

Mullen, Deborah M. ;

Wesley, David M. ;

Bergenstal, Richard M. .

DIABETES CARE, 2017, 40 (08) :994-999

[9] Pharmacological Properties of Faster-Acting Insulin Aspart [J].

Biester, Torben ;

Kordonouri, Olga ;

Danne, Thomas .

CURRENT DIABETES REPORTS, 2017, 17 (11)

[10] Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion [J].

Bode, Bruce W. ;

Johnson, Joseph A. ;

Hyveled, Liselotte ;

Tamer, Soren C. ;

Demissie, Marek .

DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (01) :25-+

← 1 2 3 4 5 6 →